Financial PerformanceMindMed ended 2024 with $274M in cash which it expects will be sufficient to fund operations into 2027.
Market PotentialMindMed's lead compound, MM120, appears positioned to disrupt the treatment paradigm for generalized anxiety disorder (GAD) and major depressive disorder (MDD), indications with high unmet need in neuropsychiatry.
Regulatory ProgressThe program is de-risked with compelling Phase 2b data demonstrating rapid, durable efficacy, and a well-aligned regulatory strategy, including Breakthrough Therapy Designation from the FDA.